Biopharmaceutical considerations in topical ocular drug delivery

Clinical and Experimental Pharmacology and Physiology

Volumn 27, Issue 7, 2000, Pages 558-562

  Davies, Nigel M ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b School of Pharmacy   (New Zealand)

Author keywords

Complexation; Cyclodextrins; Drug delivery; Eye; Formulation; Ocular bioavailability; Solubility

Indexed keywords

CYCLODEXTRIN; EYE DROPS;

CONFERENCE PAPER; CORNEA PERMEABILITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; EYE DISEASE;

ABSORPTION; ADMINISTRATION, TOPICAL; ANIMALS; BIOPHARMACEUTICS; CORNEA; EYE; HUMANS; OPHTHALMIC SOLUTIONS; SUSPENSIONS;

EID: 0034045780     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2000.03288.x     Document Type: Conference Paper

References (27)

1. 1. Mishima S, Gasset A, Klyce SD, Baum JL. Determination of tear volume and tear flow. Invest. Ophthalmol. 1966; 5: 264-76.
2. 2. Chrai SS, Patton TF, Mehta A, Robinson JR. Lacrimal and instilled fluid dynamics in rabbit eyes. J. Pharm. Sci. 1973; 62: 1112-21.
3. 3. File RR, Patton TF. Topically applied pilocarpine. Human pupillary response as a function of drop size. Arch. Ophthalmol. 1980; 98: 112-15.
4. 4. Saettone MF, Giannaccini B, Ravecca S, La Marca F, Tota G. Polymer effects on ocular bioavailability: The influence of different liquid vehicles on the mydriatic response of tropicamide in humans and in rabbits. Int. J. Pharm. 1984; 20: 187-202.
5. 5. Davies NM, Farr SJ, Hadgrafl J, Kellaway IW. Evaluation of mucoadhesive polymers in ocular drug delivery. I. Viscous solutions. Pharm. Res. 1991; 8: 1039-43.
6. 6. Gurny R, Ibrahim H, Aebi A et al. Design and evaluation of controlled release systems for the eye. J. Control. Rel. 1987; 6: 367-73.
7. 7. Ibrahim H, Bindschaedler C, Doelker E, Buri P, Gurny R. Concept and development of ophthalmic pseudo-latexes triggered by pH. Int. J. Pharm. 1991; 77: 211-19.
8. 8. Greaves JL, Wilson CG, Rozier A, Grove J, Plazonnet B. Scintigraphic assessment of an ophthalmic gelling vehicle in man and rabbit. Curr. Eye Res. 1990; 9: 415-20.
9. 9. Ahmed I, Patton TF. Disposition of timolol and inulin in the rabbit eye following corneal versus non-corneal absorption. Int. J. Pharm. 1987; 38: 9-21.
10. 10. Lee VH-L. Precorneal, corneal and postcorneal factors. In: Mitra AK (ed.). Ophthalmic Drug Delivery Systems. Marcel Dekker, New York. 1993; Ch. 3.
11. 11. Watsky MA, Jablonski MM, Edelhauser HF. Comparison of conjunctiva and corneal surface areas in rabbit and human. Curr. Eye Res. 1988; 7: 483-6.
12. 12. Wang W, Sasaki H, Chien DS, Lee VHL. Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: A comparison with corneal penetration. Curr. Eye Res. 1991; 10: 571-9.
13. 13. Lee VH-L, Robinson JR. Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits. J. Pharm. Sci. 1979; 68: 673-84.
14. 14. Schoenwald RD. Chemical delivery systems with enhanced pharmacokinetic properties. In: Mitra AK (ed.). Ophthalmic Drug Delivery Systems. Marcel Dekker, New York. 1993; Ch. 15.
15. 15. Schoenwald RD, Ward RL. Relationship between steroid permeability across excised rabbit cornea and octanol-water partition coefficients. J. Pharm. Sci. 1978; 67: 786-8.
16. 16. Kwon K, Diestelhorst M, Süverkrüp R. Dose uniformity problems of suspension eye drops. Klin. Monatsbl. Augenheilkd 1996; 209: 144-9.
17. 17. Apt L, Henrick A, Silverman LM. Patient compliance with the use of topical ophthalmic corticosteroid suspensions. Am. J. Ophthalmol. 1979; 87: 210-14.
18. 18. Sieg JW, Robinson JR. Vehicle effects on ocular drug bioavailability. I. Evaluation of fluoromethalone. J. Pharm. Sci. 1975; 64: 931-6.
19. 19. Musson DG, Bidgood AM, Olejnik O. An in vitro comparison of the permeability of prednisolone, prednisolone sodium phosphate and prednisolone acetate across the NZW rabbit cornea. J. Ocul. Pharmacol. 1992; 8: 139-50.
20. 20. Musson DG, Bidgood AM, Olejnik O. Comparative corneal penetration of prednisolone sodium phosphate and prednisolone acetate in NZW rabbits. J. Ocul. Pharmacol. 1991; 7: 175-82.
21. 21. Olejnik O, Weisbecker CA. Ocular bioavailability of topical prednisolone preparations. Clin. Ther. 1990; 12: 2-11.
22. 22. Szejtli J. Cyclodextrin technology. In: Davies JED (ed.). Topics in Inclusion Science. Kluwer, Dordrecht. 1988; Ch. 2.
23. 23. Griffiths DW, Bender ML. Cycloamyloses as catalysts. Adv. Catal. 1973; 23: 209-61.
24. 24. Davies NM, Wang G, Tucker IG. Evaluation of a hydrocortisone/ hydroxypropyl-β-cyclodextrin solution for ocular drug delivery. Int. J. Pharm. 1997; 156: 201-9.
25. 25. Jarho P, Järvinen K, Urtti A, Stella VJ, Järvinen T. Modified β-cyclodextrin (SBE7-β-CyD) with viscous vehicle improves the ocular absorption and tolerability of pilocarpine prodrug in rabbits. J. Pharm. Pharmacol. 1996; 48: 263-9.
26. 26. Usayapant A, Karara AH, Narurkar MM. Effect of 2-hydroxypropyl-β-cyclodextrin on the ocular absorption of dexamethasone and dexamethasone acetate. Pharm. Res. 1991; 8: 1495-9.
27. 27. Bary AR, Davies NM, Tucker IG. The effect of hydroxypropyl-β-cyclodextrin on the in vitro corneal permeability of hydrocortisone and correlation with in viva ocular bioavailability. Proc. Int. Symp. Control. Rel. Bioact. Mater. 1999; 26: 561-2.